414 related articles for article (PubMed ID: 12577232)
1. Review of gemcitabine in biliary tract carcinoma.
Scheithauer W
Semin Oncol; 2002 Dec; 29(6 Suppl 20):40-5. PubMed ID: 12577232
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
3. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer.
Raderer M; Hejna MH; Valencak JB; Kornek GV; Weinländer GS; Bareck E; Lenauer J; Brodowicz T; Lang F; Scheithauer W
Oncology; 1999 Apr; 56(3):177-80. PubMed ID: 10202270
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy in biliary tract carcinomas: results in India.
Doval DC; Sekhon JS; Gupta SK; Gupta S; Awasthy BS
Semin Oncol; 2002 Dec; 29(6 Suppl 20):46-50. PubMed ID: 12577233
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.
Penz M; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Lenauer A; Depisch D; Krauss G; Schneeweiss B; Scheithauer W
Ann Oncol; 2001 Feb; 12(2):183-6. PubMed ID: 11300321
[TBL] [Abstract][Full Text] [Related]
6. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma.
von Delius S; Lersch C; Schulte-Frohlinde E; Mayr M; Schmid RM; Eckel F
BMC Cancer; 2005 Jun; 5():61. PubMed ID: 15949047
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Alberts SR; Al-Khatib H; Mahoney MR; Burgart L; Cera PJ; Flynn PJ; Finch TR; Levitt R; Windschitl HE; Knost JA; Tschetter LK
Cancer; 2005 Jan; 103(1):111-8. PubMed ID: 15558814
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy for biliary tract cancer in Japan.
Okusaka T
Semin Oncol; 2002 Dec; 29(6 Suppl 20):51-3. PubMed ID: 12577234
[TBL] [Abstract][Full Text] [Related]
11. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
Kornek GV; Schuell B; Laengle F; Gruenberger T; Penz M; Karall K; Depisch D; Lang F; Scheithauer W
Ann Oncol; 2004 Mar; 15(3):478-83. PubMed ID: 14998852
[TBL] [Abstract][Full Text] [Related]
12. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma.
Thongprasert S; Napapan S; Charoentum C; Moonprakan S
Ann Oncol; 2005 Feb; 16(2):279-81. PubMed ID: 15668284
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of gemcitabine monotherapy for patients with advanced biliary tract cancer.
Yokoyama T; Yoshida H; Makino H; Maruyama H; Suzuki S; Matsutani T; Matsushita A; Hirakata A; Sasajima K; Uchida E
J Nippon Med Sch; 2012; 79(3):204-12. PubMed ID: 22791122
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy with gemcitabine in advanced biliary tract carcinoma.
Serrano A; Gerson R
Rev Recent Clin Trials; 2008 Jan; 3(1):70-8. PubMed ID: 18474016
[TBL] [Abstract][Full Text] [Related]
16. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
17. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.
Park JS; Oh SY; Kim SH; Kwon HC; Kim JS; Jin-Kim H; Kim YH
Jpn J Clin Oncol; 2005 Feb; 35(2):68-73. PubMed ID: 15709089
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Ko AH; Espinoza AM; Jones KA; Venook AP; Bergsland EK; Kelley RK; Dito E; Ong A; Hanover CS; Coakley FV; Tempero MA
Am J Clin Oncol; 2012 Oct; 35(5):411-7. PubMed ID: 21552099
[TBL] [Abstract][Full Text] [Related]
19. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]